Ceftaroline

Common Uses

Ceftaroline is used to treat several types of serious bacterial infections in adults and children. It is typically administered in a hospital or clinical setting. Its primary indications include:

• Skin Infections: It is used for acute bacterial skin and skin structure infections. This includes infections caused by methicillin-resistant Staphylococcus aureus (MRSA), which can be difficult to treat with other antibiotics.
• Pneumonia: It is used to treat community-acquired bacterial pneumonia, an infection of the lungs developed outside of a healthcare facility.

How It Works

This medication belongs to a class of drugs known as cephalosporin antibiotics. It works by stopping the growth of bacteria that cause infections. Because it targets the bacterial cell wall, it is effective against specific strains that may be resistant to other types of antibiotics.

Important Considerations

Ceftaroline is only effective against infections caused by bacteria. It will not work for viral infections, such as the common cold or the flu. Using antibiotics when they are not needed increases the risk of developing an infection later that resists antibiotic treatment.

Mechanism of Action

Ceftaroline works by disrupting the ability of bacteria to create a stable cell wall. The cell wall is a critical outer layer that bacteria need to survive, grow, and protect themselves from their surroundings.

To build this wall, bacteria use specific enzymes called penicillin-binding proteins. Ceftaroline attaches itself to these proteins, preventing them from finishing the construction of the bacterial cell wall. Without a functional wall, the bacteria become unstable and eventually burst, which leads to their death.

Key aspects of how ceftaroline works include:

• Bactericidal activity: It is designed to kill bacteria directly rather than just slowing their growth.
• Targeting resistant strains: Ceftaroline is specifically designed to bind to proteins in certain bacteria that have developed resistance to other types of antibiotics, such as methicillin-resistant Staphylococcus aureus (MRSA).
• Specific focus: This medication only works against bacterial infections and is not effective against viral infections like the common cold or the flu.

Common Side Effects

• Nausea or vomiting
• Diarrhea or constipation
• Rash or itching
• Headache
• Dizziness
• Pain, redness, or swelling at the injection site

Serious Side Effects

Seek medical attention immediately if you experience any of the following serious symptoms:

• Signs of a severe allergic reaction, including hives, swelling of the face or throat, and difficulty breathing
• Severe stomach pain and watery or bloody diarrhea, which may indicate a serious intestinal infection
• Fever, chills, or persistent sore throat
• Unusual bruising or bleeding
• Seizures
• Extreme fatigue, pale skin, or shortness of breath

Allergic Reactions

Serious and sometimes fatal allergic reactions, including anaphylaxis, have been reported. Individuals with a known hypersensitivity to penicillins, cephalosporins, or other beta-lactam antibiotics may be at a higher risk for these reactions. If a severe allergic reaction occurs, treatment is typically discontinued immediately.

Diarrhea and Colitis

Like many antibiotics, ceftaroline can cause Clostridioides difficile-associated diarrhea (CDAD). This condition ranges in severity from mild diarrhea to fatal inflammation of the colon. It occurs because the antibiotic changes the natural balance of bacteria in the gut. CDAD has been reported to occur more than two months after the completion of antibiotic therapy.

Neurological Complications

Neurological side effects, including seizures and encephalopathy, have been reported with the use of ceftaroline. These risks are particularly elevated in patients with pre-existing kidney problems if the dosage is not adjusted correctly for their level of renal function.

Blood-Related Issues

Ceftaroline may cause a positive direct Coombs' test. In some cases, this is associated with drug-induced hemolytic anemia, a condition where red blood cells are destroyed faster than they can be made. Healthcare providers may monitor blood counts if anemia develops during treatment.

Development of Drug-Resistant Bacteria

Prescribing ceftaroline in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

Pregnancy

There are no adequate and well-controlled studies of ceftaroline use in pregnant women. Animal reproduction studies have not shown evidence of harm to the fetus at doses significantly higher than those used in humans. However, because animal studies are not always predictive of human response, this medication should be used during pregnancy only if clearly needed. If you are pregnant or planning to become pregnant, discuss the potential risks and benefits with your healthcare provider.

Breastfeeding

It is not known whether ceftaroline is excreted in human milk. Because many drugs are passed into breast milk, caution should be exercised when ceftaroline is administered to a nursing woman. You should consult your doctor to discuss the risks and benefits of breastfeeding while receiving this medication.

Dosage Forms

Ceftaroline is available as a preservative-free, sterile powder in single-dose vials. It is commonly provided in a 600 milligram strength. Because it is a powder, it must be reconstituted with a compatible liquid and further diluted before it can be administered to a patient.

Administration Route

• Intravenous (IV) Infusion: The medication is delivered directly into a vein. The infusion typically lasts between 5 and 60 minutes, depending on the patient's age and the condition being treated.

This medication is only available for injection and is not produced in oral forms, such as tablets or capsules.

FDA Approval Status

Ceftaroline was first approved by the U.S. Food and Drug Administration (FDA) in 2010. It is a cephalosporin antibiotic administered via intravenous (IV) infusion. The medication is approved for use in adults and pediatric patients, including neonates (newborns).

Approved Indications

The FDA has approved ceftaroline for the treatment of specific infections caused by susceptible strains of bacteria:

• Acute Bacterial Skin and Skin Structure Infections (ABSSSI): This includes serious skin infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and other Gram-positive organisms.
• Community-Acquired Bacterial Pneumonia (CABP): This includes lung infections acquired outside of a hospital setting caused by susceptible bacteria such as Streptococcus pneumoniae.

Regulatory Requirements and Safety

Ceftaroline is a prescription-only medication. It is typically administered in a hospital or clinical setting by a healthcare professional. According to current regulatory documentation, there are no Boxed Warnings or Risk Evaluation and Mitigation Strategy (REMS) programs required for this drug. The FDA monitors the safety of the medication through ongoing post-marketing surveillance to ensure its benefits continue to outweigh its risks.

FDA-Approved Indications

The U.S. Food and Drug Administration (FDA) has approved ceftaroline fosamil for the treatment of specific infections caused by susceptible bacteria:

• Acute Bacterial Skin and Skin Structure Infections (ABSSSI): This includes infections caused by methicillin-resistant Staphylococcus aureus (MRSA).
• Community-Acquired Bacterial Pneumonia (CABP): This includes infections caused by Streptococcus pneumoniae and other specific bacteria.

Approved Patient Populations

Ceftaroline is approved for use in adults and pediatric patients, including neonates (newborns). Dosage adjustments are required for patients with certain levels of kidney impairment.

FDA Safety Warnings and Precautions

The FDA-approved labeling includes several important safety considerations:

• Hypersensitivity Reactions: Serious allergic reactions can occur. Patients with a history of severe reactions to other beta-lactam antibiotics should be monitored closely.
• Clostridioides difficile-associated Diarrhea (CDAD): This condition has been reported with nearly all systemic antibacterial agents, including ceftaroline, and can range from mild diarrhea to fatal colitis.
• Direct Coombs Test Seroconversion: A positive direct Coombs test may develop during treatment. If anemia occurs, healthcare providers must check for drug-induced hemolytic anemia.
• Neurological Adverse Reactions: Seizures and other neurological issues have been reported, particularly in patients with kidney impairment who did not receive appropriate dose adjustments.